Back to today’s briefing

Story perspectives

New Drug Reduces Resistant Hypertension: 40% Success Rate

9/4/2025

27 3 Full Breakdown

Summary

Story summary

Phase III clinical trial shows baxdrostat reduces blood pressure by 9-10 mmHg in treatment-resistant patients after 12 weeks.
About 40% of participants reached healthy blood pressure, versus under 20% in the placebo group.
The drug blocks aldosterone, targeting a major cause of difficult hypertension.
Potentially benefits 500 million people globally, including 10 million in the UK.
AstraZeneca aims for regulatory approval submission by late 2025.

1 of 1

Story summary

Phase III clinical trial shows baxdrostat reduces blood pressure by 9-10 mmHg in treatment-resistant patients after 12 weeks.
About 40% of participants reached healthy blood pressure, versus under 20% in the placebo group.
The drug blocks aldosterone, targeting a major cause of difficult hypertension.
Potentially benefits 500 million people globally, including 10 million in the UK.
AstraZeneca aims for regulatory approval submission by late 2025.